Insmed

🇺🇸United States
Ownership
-
Employees
912
Market Cap
$13.2B
Website
Introduction

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2021-10-25
Last Posted Date
2023-11-01
Lead Sponsor
Insmed Incorporated
Target Recruit Count
29
Registration Number
NCT05090904
Locations
🇺🇸

USA001, Gainesville, Florida, United States

🇺🇸

USA016, Augusta, Georgia, United States

🇺🇸

USA006, Cleveland, Ohio, United States

and more 11 locations

A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2021-03-10
Last Posted Date
2023-09-22
Lead Sponsor
Insmed Incorporated
Target Recruit Count
1
Registration Number
NCT04791514
Locations
🇺🇸

USA002, New York, New York, United States

Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

First Posted Date
2020-12-21
Last Posted Date
2024-06-28
Lead Sponsor
Insmed Incorporated
Target Recruit Count
99
Registration Number
NCT04677543
Locations
🇪🇸

ESP002, Barcelona, Spain

🇪🇸

ESP004, Madrid, Spain

🇪🇸

ESP003, Barcelona, Spain

and more 59 locations

Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

First Posted Date
2020-12-21
Last Posted Date
2024-11-25
Lead Sponsor
Insmed Incorporated
Target Recruit Count
425
Registration Number
NCT04677569
Locations
🇺🇸

USA014, Saint Petersburg, Florida, United States

🇺🇸

USA084, Sebastian, Florida, United States

🇺🇸

USA067, Tampa, Florida, United States

and more 159 locations

A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis

First Posted Date
2020-10-20
Last Posted Date
2024-11-12
Lead Sponsor
Insmed Incorporated
Target Recruit Count
1767
Registration Number
NCT04594369
Locations
🇺🇸

USA039, Kissimmee, Florida, United States

🇺🇸

USA029, Newport Beach, California, United States

🇺🇸

USA103, Plantation, Florida, United States

and more 370 locations

Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase

Phase 2
Completed
Conditions
Interventions
First Posted Date
2019-04-05
Last Posted Date
2020-07-30
Lead Sponsor
Insmed Incorporated
Target Recruit Count
49
Registration Number
NCT03905642

Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

First Posted Date
2017-07-17
Last Posted Date
2023-03-27
Lead Sponsor
Insmed Incorporated
Target Recruit Count
256
Registration Number
NCT03218917
Locations
🇧🇬

MHAT "Dr IvanSeliminski"-Sliven, Sliven, Bulgaria

🇧🇬

Cardioart Medical Center, Stara Zagora, Bulgaria

🇩🇰

Sjællands Universitetshospital, Roskilde, Roskilde, Denmark

and more 105 locations

Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212

First Posted Date
2015-12-11
Last Posted Date
2020-02-10
Lead Sponsor
Insmed Incorporated
Target Recruit Count
163
Registration Number
NCT02628600

Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone

First Posted Date
2015-01-22
Last Posted Date
2020-05-07
Lead Sponsor
Insmed Incorporated
Target Recruit Count
336
Registration Number
NCT02344004

Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection

Phase 3
Completed
Conditions
Interventions
First Posted Date
2011-03-16
Last Posted Date
2020-06-17
Lead Sponsor
Insmed Incorporated
Target Recruit Count
206
Registration Number
NCT01316276
© Copyright 2024. All Rights Reserved by MedPath